{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:38:05Z","timestamp":1792730285209,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"DOI":"10.1007\/s40268-026-00555-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:59:54Z","timestamp":1792727994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Characterization for Similarity Assessment Between Biosimilar SB16 and Denosumab Reference Product Using State-of-the-Art Analytical Method"],"prefix":"10.1007","author":[{"given":"Eunok","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misol","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanseul","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taekyung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-2476","authenticated-orcid":false,"given":"Sung-Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"8","key":"555_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/nejmoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/nejmoa0809493.","journal-title":"N Engl J Med"},{"issue":"16","key":"555_CR2","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.ccr-12-0578","volume":"18","author":"DG Branstetter","year":"2012","unstructured":"Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18(16):4415\u201324. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-0578.","journal-title":"Clin Cancer Res"},{"key":"555_CR3","unstructured":"FDA. Prolia\u00ae: FDA approval package. 2010 Jun. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125320s0000TOC.cfm. [Accessed 22 May 2025]."},{"key":"555_CR4","unstructured":"EMA. Prolia\u00ae: EPAR product information. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf. Accessed 22 May 2025."},{"key":"555_CR5","unstructured":"FDA. Xgeva\u00ae: FDA approval package. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/review\/2018\/125320Orig1s007.pdf. Accessed 22 May 2025."},{"key":"555_CR6","unstructured":"EMA. Xgeva\u00ae: EPAR product information. 2011. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf. Accessed 22 May 2025."},{"key":"555_CR7","unstructured":"EMA. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev.1. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 22 May 2025."},{"key":"555_CR8","unstructured":"US FDA. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Draft guidance for industry. CDER\/CBER; 2019. https:\/\/www.fda.gov\/media\/125484\/download. Accessed 22 May 2025."},{"key":"555_CR9","unstructured":"US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. CDER\/CBER; 2015. https:\/\/www.fda.gov\/media\/82647\/download. Accessed 22 May 2025."},{"issue":"5 Suppl.","key":"555_CR10","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2016.01.002","volume":"45","author":"A Al-Sabbagh","year":"2016","unstructured":"Al-Sabbagh A, Olech E, McClellan JE, et al. Development of biosimilars. Semin Arthritis Rheum. 2016;45(5 Suppl.):S11\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.01.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"555_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020235","volume":"17","author":"F Mascarenhas-Melo","year":"2024","unstructured":"Mascarenhas-Melo F, Diaz M, Gon\u00e7alves MBS, et al. An overview of biosimilars: development, quality, regulatory issues, and management in healthcare. Pharmaceuticals (Basel). 2024;17(2):235. https:\/\/doi.org\/10.3390\/ph17020235.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"555_CR12","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696\u2013705. https:\/\/doi.org\/10.1002\/bit.26438.","journal-title":"Biotechnol Bioeng"},{"key":"555_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.832059","volume":"10","author":"N Nupur","year":"2022","unstructured":"Nupur N, Joshi S, Gulliarme D, et al. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front Bioeng Biotechnol. 2022;10:832059. https:\/\/doi.org\/10.3389\/fbioe.2022.832059.","journal-title":"Front Bioeng Biotechnol."},{"issue":"10","key":"555_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/13543784.2023.2273510","volume":"32","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim S, Seo H. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects. Expert Opin Investig Drugs. 2023;32(10):959\u201366. https:\/\/doi.org\/10.1080\/13543784.2023.2273510.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"555_CR15","doi-asserted-by":"publisher","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","volume":"110","author":"B Langdahl","year":"2025","unstructured":"Langdahl B, Chung YS, Plebanski R, et al. Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. J Clin Endocrinol Metab. 2025;110(6):e1951\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgae611.","journal-title":"J Clin Endocrinol Metab"},{"key":"555_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117371","volume":"192","author":"YS Chung","year":"2025","unstructured":"Chung YS, Langdahl B, Plebanski R, et al. SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. Bone. 2025;192:117371. https:\/\/doi.org\/10.1016\/j.bone.2024.117371.","journal-title":"Bone"},{"issue":"1","key":"555_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40268-024-00501-6","volume":"25","author":"SY Yang","year":"2025","unstructured":"Yang SY, Lee C, Hwang K, et al. Characterization for the similarity assessment between the proposed biosimilar SB17 and ustekinumab reference product using state-of-the-art analytical methods. Drugs R D. 2025;25(1):19\u201334. https:\/\/doi.org\/10.1007\/s40268-024-00501-6.","journal-title":"Drugs R D"},{"issue":"2","key":"555_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.molimm.2012.12.005","volume":"54","author":"YD Liu","year":"2013","unstructured":"Liu YD, Wang T, Chou R, et al. IgG2 disulfide isoform conversion kinetics. Mol Immunol. 2013;54(2):217\u201326. https:\/\/doi.org\/10.1016\/j.molimm.2012.12.005.","journal-title":"Mol Immunol"},{"issue":"3","key":"555_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/elps.200900371","volume":"31","author":"NA Lacher","year":"2010","unstructured":"Lacher NA, Wang Q, Roberts RK, et al. Development of a capillary gel electrophoresis method for monitoring disulfide isomer heterogeneity in IgG2 antibodies. Electrophoresis. 2010;31(3):448\u201358. https:\/\/doi.org\/10.1002\/elps.200900371.","journal-title":"Electrophoresis"},{"issue":"1","key":"555_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2017.06.006","volume":"32","author":"E Ahern","year":"2017","unstructured":"Ahern E, Harjunpaa H, Barkauskas D, et al. Co-administration of RANKL and CTLA4 antibodies enhances cancer immunotherapy. Cancer Cell. 2017;32(1):109-24.e8. https:\/\/doi.org\/10.1016\/j.ccell.2017.06.006.","journal-title":"Cancer Cell"},{"issue":"3","key":"555_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4161\/mabs.19868","volume":"4","author":"TS Raju","year":"2012","unstructured":"Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs. 2012;4(3):385\u201391. https:\/\/doi.org\/10.4161\/mabs.19868.","journal-title":"MAbs"},{"issue":"3","key":"555_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/jps.24284","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104(3):880\u201390. https:\/\/doi.org\/10.1002\/jps.24284.","journal-title":"J Pharm Sci"},{"issue":"3","key":"555_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/btpr.1561","volume":"28","author":"A Eon-Duval","year":"2012","unstructured":"Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28(3):608\u201322. https:\/\/doi.org\/10.1002\/btpr.1561.","journal-title":"Biotechnol Prog"},{"issue":"5","key":"555_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.4161\/mabs.29883","volume":"6","author":"H Liu","year":"2014","unstructured":"Liu H, Ponniah G, Zhang HM, et al. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs. 2014;6(5):1145\u201354. https:\/\/doi.org\/10.4161\/mabs.29883.","journal-title":"MAbs"},{"issue":"2","key":"555_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","volume":"3","author":"A Wakankar","year":"2011","unstructured":"Wakankar A, Chen Y, Gokarn Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3(2):161\u201372. https:\/\/doi.org\/10.4161\/mabs.3.2.14960.","journal-title":"MAbs"},{"issue":"3","key":"555_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X","volume":"83","author":"LH Brinckerhoff","year":"1999","unstructured":"Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27\u201335) peptide: implications for peptide vaccines. Int J Cancer. 1999;83(3):326\u201334. https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19991029)83:3%3c326::AID-IJC7%3e3.0.CO;2-X.","journal-title":"Int J Cancer"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00555-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:59:55Z","timestamp":1792727995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":26,"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00555-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eunok Jung, Jinyoung Kim, Misol Do, Jihye Kim, Hanseul Kweon, Jaeil Lee, Jungmin Lee, Taekyung Yoo, and Sung-Yong Yang are employees of Samsung Bioepis Co., Ltd. Some authors may hold shares of the company as part of general employee stock ownership programs. However, none of the authors holds stock options or equity-based incentives specifically related to this manuscript or the SB16 product.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","label":"Authorship","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data sets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study design. EJ and JK contributed equally as the first authors, and MD and JK contributed equally as second authors. TY and S-YY are the corresponding authors of this article. EJ, JK, MD, JK, and HK performed the analysis, data collecting, and interpretation. The manuscript was first drafted and finalized by EJ and JK and all authors participated in the review and revision of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}